Arcturus extends CF Foundation deal; total funding up to ~$25M for ARCT-032 CF program

Arcturus Therapeutics Holdings Inc.

CF Foundation increases financial commitment to ~$25M to advance ARCT-032, an mRNA therapeutic for cystic fibrosis.
Arcturus to provide $15M in matching funds; royalty rates and caps modified with option to reduce via one-time payment.
Agreement extends prior program initiated in 2017; Phase 1b study in adults with CF planned imminently.
ARCT-032 is mutation-agnostic and aims to express functional CFTR protein in the lung, addressing root cause of CF.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. amended the "Amendment" with Cystic Fibrosis Foundation valued at up to $9 million (effective 2023-09-25).

Action: amendment
Agreement: collaboration
Counterparty: Cystic Fibrosis Foundation
Value: up to $9 million
Effective: 2023-09-25

Exact text from the filing

On September 25, 2023, Arcturus Therapeutics, Inc. (" Arcturus "), a subsidiary of Arcturus Therapeutics Holdings Inc. (the " Company "), entered into an amendment (the " Amendment ") to its Development Program Letter Agreement of May 16, 2017

View on SEC.gov

Browse all material agreements →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-23-001328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.